Search

Displaying results 1971 - 1980 of 9667 in total
  1. Drug

    Lisocabtagene maraleucel

    go.drugbank.com/drugs/DB16582
    ApprovedInvestigational

    [A228493] Lisocabtagene maraleucel was granted FDA approval on 5 February 2021 [L31583] and EC approval on 5 April 2022.[L42210] It was later granted Health Canada approval on 6 May 2022. … [L31588] CAR T-cell therapy has changed the treatment of B-cell lymphomas, significantly increasing survival rates over standard therapy.

    Categories: CD19-Directed Genetically Modified Autologous T-cell Immunotherapies
  2. Drug

    Toripalimab

    go.drugbank.com/drugs/DB15043
    ApprovedInvestigational

    It was first approved in China in December 2018 for the treatment of unresectable or metastatic melanoma in previously treated patients. … [A262011,A262591] Toripalimab was granted FDA approval in October 2023 for the treatment of select patients with nasopharyngeal carcinomas.[L48696]

  3. Drug

    Clove oil

    go.drugbank.com/drugs/DB11338
    ApprovedNutraceutical

    Traditionally, it has been used as a flavouring spice in foods, or as a fragrance. It is also found in topical analgesics. Clove oil has shown to exert some antimicrobial activities. … The FDA categorizes clove oil as generally recognized as safe (GRAS) for use in dental cement or as a food additive [F108].

  4. Drug

    Flortaucipir F-18

    go.drugbank.com/drugs/DB14914
    ApprovedInvestigational

    [A203933] It is used as a marker in positron emission tomography (PET) imaging of patients suspected of having Alzheimer's disease. … , as well as to regions containing high levels of melanin, neuromelanin, and iron.

  5. Drug

    Sugemalimab

    go.drugbank.com/drugs/DB16641
    ApprovedInvestigational

    to treat T-cell lymphoma. … [L53398] During studies, sugemalimab was well tolerated and has shown antitumor activity in multiple tumor types.

  6. Drug

    Mobocertinib

    go.drugbank.com/drugs/DB16390
    ApprovedInvestigationalWithdrawn

    as compared to "classical" _EGFR_ mutants causing NSCLC) and are associated with resistance to standard targeted EGFR inhibitors. … It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the _EGFR_ gene,[L38368] which are typically associated with a poorer prognosis (

  7. Drug

    Meningococcal polysaccharide vaccine group A

    go.drugbank.com/drugs/DB13889
    ApprovedInvestigational

    It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup A.

    Mixtures: Mencevax Ac Pws 50mcg/vial, Mencevax Ac Pws 500mcg/vial
  8. Drug

    Piperonyl butoxide

    go.drugbank.com/drugs/DB09350
    ApprovedVet approved

    It has no pesticidal activity of its own, but acts to increase the activity of pesticides such as carbamates, pyrethrins, pyrethroids, and rotenone. … Piperonyl butoxide (PBO) is an organic compound used as a component of pesticide formulations. It is used for the treatment of head, pubic (crab), and body lice. Piperonyl butoxide is a synergist.

    Mixtures: El piojito Lice Killing, good neighbor pharmacy Lice
  9. Drug

    Debrisoquine

    go.drugbank.com/drugs/DB04840
    Approved

    It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. … They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.

  10. Target

    Methyl-accepting chemotaxis protein II

    go.drugbank.com/bio_entities/BE0001434
    TargetSalmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)

    Receptor for the attractant L-aspartate and related amino and dicarboxylic acids. Tar mediates taxis away from the repellents cobalt and nickel. Unlike in E.coli tar, it does not mediate maltose taxis.

    Synonyms: cheM